https://pbs.twimg.com/media/FhdIhgVWQAEduRu.jpg
Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0

Links:

A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics an… http://ow.ly/rAhC50Lxr86
Dr. Rachel Tate
uptoTate
13-11-2022
×